Divarasib

• Description :

  Divarasib (GDC-6036) is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds to the switch II (SW-II) pocket of KRAS G12C and irreversibly locks it in the inactive GDP-bound state.

• Product Name Alternative :

  GDC-6036

• UNSPSC :

  12352005

• Target :

  Ras

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/divarasib.html

• Purity :

  99.31

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  NC1=N[C@]([C@]2=C(C=C3C(N=C(N=C3N4[C@H](CN(CC4)C(C=C)=O)C)OC[C@H]5N(CCC5)C)=C2F)Cl)=C(C(C)=C1)C(F)(F)F

• Molecular Formula :

  C29H32ClF4N7O2

• Molecular Weight :

  622.06

• References & Citations :

  [1]Sushant Malhotra, et al. Fused ring compounds. WO2020097537A2.|[2]Lingyao Meng, et al. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. Anal Chem. 2022 Sep 20;94 (37) :12927-12933.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  K-Ras

• CAS Number :

  [2417987-45-0]